AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9498258 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin 2 x 100 U/kg/d s.c. for 4 weeks (n = 90)
Number of subjects: 334
Study 9498258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 2 x 250 mg/d and low molecular weight heparin 2 x 100 U/kg/d s.c. for 4 weeks (n = 72)
Number of subjects: 334
Study 9498258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 2 x 250 mg/d for 4 weeks (n = 125)
Number of subjects: 334
Study 9498258 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy (phenprocoumon and low molecular weight heparin)
Number of subjects: 334
Study 9498258 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and ticlopidine
Number of subjects: 334
Study 9498258 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenprocoumon and low molecular weight heparin
Number of subjects: 334
Study 7623360 — intervention group
Group type: EXPERIMENTAL
Intervention: Manchester procedure (MP)
Number of subjects: 193
Study 7623360 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy (VH)
Number of subjects: 193
Study 2695866 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive containing cyproterone acetate
Number of subjects: 66
Study 2695866 — intervention group
Group type: EXPERIMENTAL
Intervention: Other low-dose oral contraceptives (desogestrel, gestodene)
Number of subjects: 66
Study 2695866 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 66
Study 340141 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (15 mg) plus Paracetamol (500 mg)
Number of subjects: 167
Study 340141 — intervention group
Group type: COMPARATOR
Intervention: Dextropropoxyphene hydrochloride (32.5 mg) plus Paracetamol (325 mg)
Number of subjects: 167
Study 7361103 — intervention group
Group type: EXPERIMENTAL
Intervention: Blend of seven artificial colors
Number of subjects: 22
Study 31743571 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano hydroxyapatite bone substitute
Number of subjects: 20
Study 31743571 — intervention group
Group type: COMPARATOR
Intervention: Tent group (graftless tenting technique)
Number of subjects: 20
Study 28678345 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) with reduced calorie consumption and increased physical activity designed to achieve and maintain ≥7% weight loss
Number of subjects: 5145
Study 28678345 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education intervention (DSE)
Number of subjects: 5145
Study 26373822 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise (40-min single bout) in PCOS group
Number of subjects: 27
Study 26373822 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise (40-min single bout) in CTRL group
Number of subjects: 27
Study 26373822 — intervention group
Group type: COMPARATOR
Intervention: Acute exercise (40-min single bout) in both PCOS and CTRL groups
Number of subjects: 27
Study 23678117 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinergic transients observed during signal-hit trials (incongruent hits)
Number of subjects: 0
Study 23678117 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent hits activating right rostral PFC (Brodmann area 10)
Number of subjects: 0
Study 23678117 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of tissue oxygen as a proxy for BOLD in rats
Number of subjects: 0
Study 21488750 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH) 18-54 mg/day
Number of subjects: 78
Study 21488750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 19773644 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine ethyl ester supplementation
Number of subjects: 0
Study 19773644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17689968 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (VAN) 15 mg/kg
Number of subjects: 22
Study 17689968 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (TEC) 8 mg/kg
Number of subjects: 22
Study 15071872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve block (ICB) using 0.25% bupivacaine before operation
Number of subjects: 30
Study 15071872 — intervention group
Group type: COMPARATOR
Intervention: Control group with chest tube insertion (Group CT)
Number of subjects: 30
Study 11860326 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI survivors
Number of subjects: 23
Study 11860326 — intervention group
Group type: COMPARATOR
Intervention: Young adults without neurological impairment
Number of subjects: 23
Study 10643541 — intervention group
Group type: EXPERIMENTAL
Intervention: EPOCH regimen (etoposide 50 mg/m2, vincristine 0.4 mg/m2, doxorubicin 10 mg/m2 continuous infusion days 1-4; cyclophosphamide 750 mg/m2 i.v. bolus day 6; prednisone 60 mg/m2 days 1-6)
Number of subjects: 78
Study 10643541 — intervention group
Group type: COMPARATOR
Intervention: CHOP regimen (as routinely prescribed)
Number of subjects: 78
Study 10643541 — intervention group
Group type: EXPERIMENTAL
Intervention: EPOCH regimen
Number of subjects: 78
Study 10643541 — intervention group
Group type: COMPARATOR
Intervention: CHOP regimen
Number of subjects: 78
Study 7605854 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg p.o. daily
Number of subjects: 229
Study 7605854 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg p.o. daily
Number of subjects: 229
Study 7605854 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg p.o. b.d.
Number of subjects: 229
Study 2132340 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual oximetry using Edwards catheter
Number of subjects: 30
Study 2132340 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual oximetry using Spectramed catheter
Number of subjects: 30
Study 2132340 — intervention group
Group type: COMPARATOR
Intervention: Transition from two-lung ventilation (2LV) to one-lung ventilation (1LV)
Number of subjects: 30
Study 2132340 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oximetry
Number of subjects: 30
Study 2132340 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring SvO2
Number of subjects: 30
Study 734581 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral tilt
Number of subjects: 75
Study 734581 — intervention group
Group type: COMPARATOR
Intervention: Right lateral tilt
Number of subjects: 75
Study 30902094 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily electronic patient-reported outcome (PRO) diary
Number of subjects: 1989
Study 27872058 — intervention group
Group type: EXPERIMENTAL
Intervention: Lestaurtinib (CEP701)
Number of subjects: 500
Study 27872058 — intervention group
Group type: COMPARATOR
Intervention: Control (no lestaurtinib)
Number of subjects: 500
Study 24919961 — intervention group
Group type: EXPERIMENTAL
Intervention: VIPP-AUTI
Number of subjects: 78
Study 24919961 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 78
Study 23478059 — intervention group
Group type: EXPERIMENTAL
Intervention: Abagovomab 2 mg administered as 1‐mL suspension once every 2 weeks for 6 weeks (induction phase) and then once every 4 weeks (maintenance phase) until recurrence or up to 21 months after random assignment of the last patient.
Number of subjects: 888
Study 23478059 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered as 1‐mL suspension once every 2 weeks for 6 weeks (induction phase) and then once every 4 weeks (maintenance phase) until recurrence or up to 21 months after random assignment of the last patient.
Number of subjects: 888
Study 23478059 — intervention group
Group type: EXPERIMENTAL
Intervention: Abagovomab
Number of subjects: 888
Study 21777052 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat acclimation (10 days)
Number of subjects: 8
Study 21777052 — intervention group
Group type: COMPARATOR
Intervention: Pre-cooling (20 min with ice packs)
Number of subjects: 8
Study 21777052 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (no pre-cooling)
Number of subjects: 8
Study 19210857 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily fish diet (four portions per week)
Number of subjects: 25
Study 19210857 — intervention group
Group type: COMPARATOR
Intervention: Red meat diet (four portions per week)
Number of subjects: 25
Study 16458970 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-Tenon's capsule injection of 20 mg triamcinolone acetonide (TA)
Number of subjects: 10
Study 16458970 — intervention group
Group type: COMPARATOR
Intervention: Control eye (no TA injection)
Number of subjects: 10
Study 15255456 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 110
Study 15255456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 15255456 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (recent onset AF with spontaneous conversion)
Number of subjects: 110
Study 15255456 — intervention group
Group type: COMPARATOR
Intervention: Placebo (recent onset AF with spontaneous conversion)
Number of subjects: 110
Study 15255456 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (persistent AF)
Number of subjects: 110
Study 15255456 — intervention group
Group type: COMPARATOR
Intervention: Placebo (persistent AF)
Number of subjects: 110
Study 11966483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (50 microg, 4 times at 4 hour intervals)
Number of subjects: 100
Study 11966483 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion (starting at 1 mIU/min, increasing every 30 minutes up to 30 mIU/min)
Number of subjects: 100
Study 11966483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 100
Study 11966483 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion
Number of subjects: 100
Study 9809179 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric training
Number of subjects: 28
Study 9809179 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training
Number of subjects: 28
Study 9809179 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both concentric and eccentric training
Number of subjects: 28
Study 9809179 — intervention group
Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 28
Study 7897876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia
Number of subjects: 40
Study 7897876 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 40
Study 2676911 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of 18,000 IE retinol, 70 mg L‐cystine, and 7000 mg gelatin
Number of subjects: 83
Study 2676911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 365487 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin (375 mg/d three times i.m.)
Number of subjects: 25
Study 365487 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin (80 mg/d three times i.m.)
Number of subjects: 25
Study 31678988 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and nutritional advice (Intervention Group)
Number of subjects: 98
Study 31678988 — intervention group
Group type: COMPARATOR
Intervention: Theoretical-practical sessions on nutrition (Control Group)
Number of subjects: 98
Study 30114561 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin (4500 IU daily until 37 gestational weeks)
Number of subjects: 53
Study 30114561 — intervention group
Group type: COMPARATOR
Intervention: No tinzaparin (control group)
Number of subjects: 53
Study 27176661 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOICES (information plus counseling; IPC)
Number of subjects: 830
Study 27176661 — intervention group
Group type: COMPARATOR
Intervention: Information only (IO)
Number of subjects: 830
Study 25197922 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized 9-mg sodium hyaluronate nasal washes plus saline solution
Number of subjects: 39
Study 25197922 — intervention group
Group type: COMPARATOR
Intervention: Saline alone (5 mL)
Number of subjects: 39
Study 22276958 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 890
Study 20093905 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (n=59)
Number of subjects: 109
Study 20093905 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=50)
Number of subjects: 109
Study 17396441 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU/m2 IFN-alpha therapy for 6 months
Number of subjects: 68
Study 17396441 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 MU/m2 IFN-alpha therapy for 6 months
Number of subjects: 68
Study 17396441 — intervention group
Group type: COMPARATOR
Intervention: Both groups combined
Number of subjects: 68
Study 15618257 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical abortion (600 mg mifepristone followed by 1 mg gemeprost)
Number of subjects: 1033
Study 15618257 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical abortion (vacuum aspiration in general anaesthesia)
Number of subjects: 1033
Study 15618257 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed medical abortion
Number of subjects: 1033
Study 15618257 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed surgical abortion
Number of subjects: 1033
Study 11860971 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic laser therapy (16 eyes)
Number of subjects: 29
Study 11860971 — intervention group
Group type: COMPARATOR
Intervention: No treatment (19 eyes)
Number of subjects: 29
Study 10624637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 36
Study 10624637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 36
Study 10624637 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 36
Study 7728784 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' judgment on a 1-5 scale (1 = no suspicion; 5 = convinced) regarding AMI suspicion before interpreting ECG.
Number of subjects: 0
Study 2028775 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear meniscus cytology
Number of subjects: 200
Study 2028775 — intervention group
Group type: COMPARATOR
Intervention: Conjunctival fluid cytology
Number of subjects: 200
Study 6112842 — intervention group
Group type: EXPERIMENTAL
Intervention: Active antiparkinson (AP) medication
Number of subjects: 100
Study 6112842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31168590 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine Colostrum (BC)
Number of subjects: 160
Study 31168590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 30716938 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberries grown on biodegradable mulch
Number of subjects: 1510
Study 30716938 — intervention group
Group type: EXPERIMENTAL
Intervention: Information treatment on biodegradable mulches
Number of subjects: 1510
Study 30716938 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors (female, higher income, stronger environment-friendly attitudes)
Number of subjects: 1510
Study 28944357 — intervention group
Group type: EXPERIMENTAL
Intervention: Endodontic retreatment
Number of subjects: 40
Study 28944357 — intervention group
Group type: COMPARATOR
Intervention: Implant-supported crown
Number of subjects: 40
Study 26755507 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib 300 mg by intravenous infusion every 3 weeks
Number of subjects: 109
Study 26755507 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice of single-agent, nonplatinum, cytotoxic chemotherapy)
Number of subjects: 109
Study 23511382 — intervention group
Group type: EXPERIMENTAL
Intervention: Threatening information
Number of subjects: 63
Study 23511382 — intervention group
Group type: COMPARATOR
Intervention: Nonthreatening information
Number of subjects: 63
Study 22521755 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet group (n = 42)
Number of subjects: 112
Study 22521755 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one group (n = 46)
Number of subjects: 112
Study 22521755 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 24)
Number of subjects: 112
Study 19643483 — intervention group
Group type: EXPERIMENTAL
Intervention: Besifloxacin ophthalmic suspension 0.6%
Number of subjects: 1161
Study 19643483 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin ophthalmic solution 0.5%
Number of subjects: 1161
Study 17957450 — intervention group
Group type: EXPERIMENTAL
Intervention: Reports of a work compensation claim within the year previous to baseline (females)
Number of subjects: 5604
Study 17957450 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of health anxiety (females)
Number of subjects: 5604
Study 17957450 — intervention group
Group type: EXPERIMENTAL
Intervention: One or more contacts to the general practitioner in the year previous to baseline (females)
Number of subjects: 5604
Study 17957450 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported poor leadership quality at work (females)
Number of subjects: 5604
Study 17957450 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of health anxiety (males)
Number of subjects: 5604
Study 17957450 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive work (males)
Number of subjects: 5604
Study 15751665 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin during CPB in patients with postoperative SIRS (Group B)
Number of subjects: 32
Study 15751665 — intervention group
Group type: COMPARATOR
Intervention: Control group A (normal postoperative course)
Number of subjects: 32
Study 15751665 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory parameters in SIRS group
Number of subjects: 32
Study 12061965 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-handed lifting with two feet
Number of subjects: 24
Study 12061965 — intervention group
Group type: EXPERIMENTAL
Intervention: One-handed supported lifting
Number of subjects: 24
Study 12061965 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting from the upper front region of the bin
Number of subjects: 24
Study 12061965 — intervention group
Group type: EXPERIMENTAL
Intervention: Bin design with a hand hold
Number of subjects: 24
Study 9858352 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin 2.4 million units intramuscularly once
Number of subjects: 525
Study 9858352 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin plus amoxicillin 2 g and probenecid 500 mg orally three times daily for 10 days
Number of subjects: 525
Study 7878752 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine flow immunocytometry (UFC)
Number of subjects: 40
Study 7878752 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine cytology (UC)
Number of subjects: 40
Study 7878752 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of UC and UFC
Number of subjects: 40
Study 1454956 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (exposed to a distinctive stimulus before each infusion of chemotherapy)
Number of subjects: 0
Study 1454956 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study 6230999 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1.5% erythromycin solution
Number of subjects: 154
Study 6230999 — intervention group
Group type: COMPARATOR
Intervention: Topical 1% clindamycin phosphate solution
Number of subjects: 154
Study 30759445 — intervention group
Group type: EXPERIMENTAL
Intervention: TEM-CAP
Number of subjects: 247
Study 30759445 — intervention group
Group type: COMPARATOR
Intervention: 5FU-DTIC
Number of subjects: 247
Study 30077032 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyphoplasty (KP)
Number of subjects: 46
Study 30077032 — intervention group
Group type: COMPARATOR
Intervention: Vertebroplasty (VP)
Number of subjects: 46
Study 26715213 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 400 mg (EFV400)
Number of subjects: 606
Study 26715213 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz 600 mg (EFV600)
Number of subjects: 606
Study 26715213 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2B6 983TC/CC genotype
Number of subjects: 606
Study 26715213 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2B6 15582CT/TT and ABCB1 3435TT genotypes
Number of subjects: 606
Study 26715213 — intervention group
Group type: EXPERIMENTAL
Intervention: C12 between 0.47 and 0.76 mg/L
Number of subjects: 606
Study 25637886 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaining abstinence (defined as achieving seven-day point prevalent abstinence at any post-initial abstinence assessment)
Number of subjects: 287
Study 23609378 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical antipsychotics (TAs)
Number of subjects: 308
Study 23609378 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 308
Study 23609378 — intervention group
Group type: COMPARATOR
Intervention: Nonclozapine atypical antipsychotics (AAs)
Number of subjects: 308
Study 21045576 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based education intervention
Number of subjects: 0
Study 18235202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir 50 mg/ml
Number of subjects: 29
Study 18235202 — intervention group
Group type: COMPARATOR
Intervention: NaCl 9% (placebo)
Number of subjects: 29
Study 18235202 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 17000819 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intraoperative and postoperative analgesic regimen (morphine sulfate, diclofenac, dextropropoxyphene hydrochloride + acetaminophen prn)
Number of subjects: 29
Study 17000819 — intervention group
Group type: COMPARATOR
Intervention: Continuous paravertebral block (for 48 h) and acetaminophen and parecoxib (followed by celecoxib up to 5 days)
Number of subjects: 29
Study 17000819 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a pain rating index = 0 (n = 11)
Number of subjects: 29
Study 17000819 — intervention group
Group type: COMPARATOR
Intervention: Patients with a pain rating index > or =1 (n = 18)
Number of subjects: 29
Study 17000819 — intervention group
Group type: EXPERIMENTAL
Intervention: Group N (continuous paravertebral block)
Number of subjects: 29
Study 14582587 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief information + occlusal appliance (BI + OA)
Number of subjects: 122
Study 14582587 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief information + relaxation therapy (BI + RT)
Number of subjects: 122
Study 14582587 — intervention group
Group type: COMPARATOR
Intervention: Brief information (BI)
Number of subjects: 122